Answers are grounded in this paper and cite their sources.
Sub-visible particles (SvPs) in parenteral drug products present patient safety and product quality risks. While Micro-Flow Imaging (MFI) and FlowCam are established for SvP enumeration and morphological assessments, inferring particle identity and origin from images alone remains challenging due to diverse inherent, intrinsic, and extrinsic sources, as well as stress-induced changes in particle populations. This study developed and evaluated a deep-learning workflow that integrates transfer-learning feature extraction with anomaly detection and similarity search to improve ground truth label quality and supervised classification to differentiate proteinaceous and non-proteinaceous SvPs. A comprehensive panel of SvP types relevant to biologicsincluding protein aggregates generated under thermal, pH, mixing, and agitation stresses; fatty acids; silicone oil droplets; elastomeric stopper particles; glass lamellae; and fibrous contaminantswas imaged on both FlowCam and MFI. Subject matter experts curated labels, and features extracted via VGG16/ResNet50 informed anomaly detection for label/quality control. Three classifiers (a baseline CNN, DenseNet121, and YOLOv8) were evaluated and benchmarked. Across models built with particle images of varying sizes (5−10 μm, 10−25 μm, >15 μm, and >25 μm), YOLOv8 achieved the highest performance (FlowCam: accuracy 0.973; MFI: accuracy 0.918), with strong precision/recall and specificity, outperforming both the baseline CNN and DenseNet121. Clustering analyses further revealed separations between protein vs non-protein SvPs and showed the model’s potential ability to distinguish stress-specific protein aggregates across multiple molecules, suggesting potential utility in root-cause analysis during development and manufacturing. This comparative, cross-platform study highlights the value of modern classification architectures as a complementary SvP identification tool to confirmatory spectroscopies (e.g., Raman/FTIR), thereby improving process understanding within biologics development.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: